A new experimental injection from Merck has shown encouraging results in a clinical trial for diabetic macular edema.
The drug, Remigromig, met the main goal of a 52-week trial involving 984 patients with the diabetes-related eye condition. It achieved the required standard for improving visual acuity and was non-inferior to ranibizumab, an established treatment.
The findings could open another path for treating retinal vascular diseases. However, further safety analysis and detailed trial results remain important before the drug’s potential can be fully assessed.
How Remigromig Works
Remigromig is an experimental injection designed to activate the Wnt pathway. This pathway plays a role in the repair and maintenance of the blood-retinal barrier.
The treatment aims to strengthen the protective lining of retinal blood vessels. As a result, it could help reduce fluid leakage into the eye.
In the BRUNELLO trial, researchers tested two doses of Remigromig against 0.5mg ranibizumab. Both Remigromig doses met the non-inferiority goal for changes in best-corrected visual acuity after 52 weeks.
What Is Diabetic Macular Edema?
Diabetic macular edema develops when diabetes damages blood vessels in the retina. These damaged vessels can leak fluid, causing swelling in the macula.
The macula is the central part of the retina responsible for sharp and detailed vision. Therefore, swelling in this area can affect a person’s central vision and potentially lead to vision loss.
Current treatments include anti-VEGF injections, laser therapy and steroid injections or implants. Ranibizumab is an anti-VEGF treatment that helps control abnormal blood vessel growth and leakage.
Safety Remains an Important Question
Merck said Remigromig was generally tolerated by patients during the trial. However, some complications occurred more frequently in patients receiving the experimental drug.
The company reported higher rates of proliferative diabetic retinopathy and vitreous hemorrhage. Treatment discontinuations linked to adverse events were also higher with Remigromig than with ranibizumab. Further analysis is underway to better understand these findings.
Analyst Evan Seigerman of BMO Capital Markets said detailed trial results and supporting data would be needed to assess the drug’s commercial potential.
He further noted that safety would remain an important consideration as the findings are evaluated.
Merck Plans Further Research
Merck is continuing to study Remigromig for other retinal diseases. These include neovascular age-related macular degeneration and retinal vein occlusion.
The company is also evaluating the drug in another Phase 2b/3 trial for diabetic macular edema.
Meanwhile, Merck plans to present the latest BRUNELLO findings at the annual meeting of the American Academy of Ophthalmology in October. The detailed results are expected to provide a clearer picture of the treatment’s effectiveness and safety.
For now, the trial results show that Remigromig achieved its primary visual-acuity goal against ranibizumab. However, additional data will be needed to determine its future role in treating diabetic macular edema.
For the latest updates, visit and follow The Truth International website (www.thetruthinternational.com) and subscribe to the YouTube Channel.
